Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.
Integrase Inhibitors Related Products:
Dolutegravir sodium; Raltegravir; Raltegravir potassium; Dolutegravir